חוב לטווח ארוך של החברה: Evaxion Biotech (EVAX)

Evaxion Biotech A/S (EVAX) integrates immunology with AI, attracting leading specialists to develop personalized vaccines. Historical price action on the GURU.Markets platform shows that long-term debt stands at 0.01. The company relies on external cloud resources for neural network training, which pressures profits. Meanwhile, management is actively implementing algorithms into cancer drug discovery through alliances with pharmaceutical behemoths.

This indicator measures the aggregate of liabilities with a maturity exceeding one year, reflecting the capital raising strategy for scaling the business and the long-term solvency of Evaxion Biotech A/S (EVAX). By analyzing the current level of the organization's long-term financial debt, the investor assesses the balance between credit risk and investments in the clinical validation of melanoma vaccines and the development of personalized treatment algorithms.